Clearmind Medicine Inc., a biotechnology company incorporated in Canada, has successfully completed an exempt offering of securities, raising $2.4 million USD as per a new notice filed with the U.S. Securities and Exchange Commission (SEC) on January 11, 2024. The offering, which did not last more than a year, included equity, options, warrants, and other rights to acquire securities. The company, led by CEO Dr. Adi Zuloff-Shani, has indicated that none of the proceeds will be used for payments to its executive officers, directors, or promoters. Aegis Capital Corp. was involved in the transaction, receiving sales commissions estimated at $192,000 USD. The offering was made under Rule 506(b) of Regulation D, which allows for the sale of securities without SEC registration, provided certain conditions are met. Clearmind Medicine has confirmed that all securities have been sold, with a total of 12 investors participating in the offering.

Clearmind Medicine Inc., a biotechnology company incorporated in Canada, has successfully completed an exempt offering of securities, raising $2.4 million USD as per a new notice filed with the U.S. Securities and Exchange Commission (SEC) on January 11, 2024. The offering, which did not last more than a year, included equity, options, warrants, and other rights to acquire securities. The company, led by CEO Dr. Adi Zuloff-Shani, has indicated that none of the proceeds will be used for payments to its executive officers, directors, or promoters. Aegis Capital Corp. was involved in the transaction, receiving sales commissions estimated at $192,000 USD. The offering was made under Rule 506(b) of Regulation D, which allows for the sale of securities without SEC registration, provided certain conditions are met. Clearmind Medicine has confirmed that all securities have been sold, with a total of 12 investors participating in the offering.